IGC Pharma, Inc. (IGC)
(Real Time Quote from BATS)
$0.36 USD
0.00 (-0.55%)
Updated Oct 4, 2024 03:08 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Cash flow Statements
Fiscal Year End for IGC Pharma, Inc falls in the month of March.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -13.00 | -11.51 | -15.02 | -8.81 | -7.32 |
Depreciation/Amortization & Depletion | 0.64 | 0.66 | 0.65 | 0.48 | 0.14 |
Net Change from Assets/Liabilities | 1.89 | 0.79 | 2.54 | -3.29 | -3.06 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 5.27 | 3.01 | 4.37 | 0.83 | 1.55 |
Net Cash From Operating Activities | -5.20 | -7.05 | -7.46 | -10.80 | -8.68 |
Property & Equipment | -0.09 | 0.23 | -0.21 | -1.42 | -4.39 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.15 | -0.15 | 0.00 | 4.93 | -5.08 |
Other Investing Activities | -0.38 | -0.31 | -0.54 | -0.12 | -0.08 |
Net Cash from Investing Activities | -0.32 | -0.24 | -0.74 | 3.39 | -9.55 |
Uses of Funds
3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 3.53 | 0.10 | 4.15 | 14.16 | -0.06 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.53 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 3.52 | 0.10 | 4.14 | 14.69 | -0.06 |
Effect of Exchange Rate Changes | -0.01 | -0.08 | -0.03 | 0.02 | -0.07 |
Net Change In Cash & Equivalents | -2.00 | -7.26 | -4.09 | 7.29 | -18.35 |
Cash at Beginning of Period | 3.20 | 10.46 | 14.55 | 7.26 | 25.61 |
Cash at End of Period | 1.20 | 3.20 | 10.46 | 14.55 | 7.26 |
Diluted Net EPS | -0.22 | -0.22 | -0.30 | -0.21 | -0.19 |
Fiscal Year End for IGC Pharma, Inc falls in the month of March.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -2.38 | -13.00 | -10.12 | -4.53 | -2.08 |
Depreciation/Amortization & Depletion | 0.16 | 0.64 | 0.47 | 0.31 | 0.16 |
Net Change from Assets/Liabilities | 0.06 | 1.89 | 0.22 | 0.27 | 0.15 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 0.40 | 5.27 | 4.75 | 0.86 | 0.30 |
Net Cash From Operating Activities | -1.75 | -5.20 | -4.67 | -3.09 | -1.47 |
Property & Equipment | -0.04 | -0.09 | -0.08 | -0.01 | 0.02 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.15 | 0.15 | 0.13 | 0.00 |
Other Investing Activities | -0.09 | -0.38 | -0.07 | -0.05 | -0.03 |
Net Cash from Investing Activities | -0.13 | -0.32 | 0.01 | 0.07 | -0.01 |
Uses of Funds
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 2.51 | 3.53 | 2.86 | 2.86 | 0.00 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 2.51 | 3.52 | 2.86 | 2.86 | 0.00 |
Effect of Exchange Rate Changes | 0.00 | -0.01 | -0.01 | -0.01 | 0.00 |
Net Change In Cash & Equivalents | 0.63 | -2.00 | -1.82 | -0.17 | -1.47 |
Cash at Beginning of Period | 1.20 | 3.20 | 3.20 | 3.20 | 3.20 |
Cash at End of Period | 1.82 | 1.20 | 1.38 | 3.03 | 1.72 |
Diluted Net EPS | -0.03 | -0.04 | -0.09 | -0.05 | -0.04 |